Franklin Berger

Franklin Berger

Direktor/Vorstandsmitglied bei ATEA PHARMACEUTICALS, INC.

Vermögen: 9 Mio $ am 30.09.2026

76 Jahre
Health Technology
Finance
Consumer Services

Profil

Mr. Franklin M.
Berger
, CFA MBA, is an Independent Director at Retension Pharmaceuticals, Inc., a Lead Independent Director at Atea Pharmaceuticals, Inc., a Senior Advisor at Qiming US Ventures Management, LLC and a Managing Director at FMB Research.
He is on the Board of Directors at Retension Pharmaceuticals, Inc., Satellos Bioscience, Inc., Atea Pharmaceuticals, Inc. and Walking Fish Therapeutics, Inc. Mr. Berger was previously employed as a Lead Independent Director by Rain Oncology, Inc., a Chairman by Proteostasis Therapeutics, Inc., an Independent Director by ESSA Pharma, Inc., an Independent Director by Atreca, Inc., an Independent Director by Tocagen, Inc., an Independent Director by Immune Design Corp., an Independent Director by BioTime, Inc., an Independent Director by Five Prime Therapeutics, Inc., an Independent Director by BELLUS Health, Inc., a Lead Independent Director by Thallion Pharmaceuticals, Inc., a Senior Manager-Portfolio by NEMO Fund, Inc., a Senior Manager-Investment by Sectoral Asset Management, Inc., an Independent Director by Seattle Genetics, Inc., a Managing Director-Equity Research by JPMorgan Securities, Inc., a Managing Director-Equity Research by Salomon Smith Barney, Inc., a Director-Equity Research by Smith Barney Asset Management, a Managing Director-Equity Research by Josephthal, Lyon & Ross, Inc., and an Advisor by Brookline Capital Acquisition Corp.
He also served on the board at Applied Therapeutics, Inc., Kezar Life Sciences, Inc., Emisphere Technologies, Inc., Isotechnika Pharma, Inc., Isotechnika, Inc., VaxGen, Inc., Alzheon, Inc., Asterias Biotherapeutics, Inc., Aurinia Pharmaceuticals, Inc., Caprion Proteomics, Inc., CellCarta Biosciences, Inc., Episcopal Relief & Development Corp., HealthShares, Inc., iTherX Pharmaceuticals, Inc., The Genetics Co., Inc. and ViroChem Pharma, Inc.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
18.08.2026 690’067 ( 3.25% ) 6 Mio $ 30.09.2026
18.06.2026 536’097 ( 0.67% ) 3 Mio $ 30.09.2026
0.27%
13.10.2026 22’517 ( 0.27% ) 237 104 $ 30.09.2026

Aktive Positionen von Franklin Berger

UnternehmenPositionBeginn
ATEA PHARMACEUTICALS, INC. Direktor/Vorstandsmitglied 01.09.2019
SATELLOS BIOSCIENCE INC. Direktor/Vorstandsmitglied 29.06.2023
Vorstandsvorsitzender 01.06.2005
Berater 01.01.2019
Direktor/Vorstandsmitglied -

Ehemalige bekannte Positionen von Franklin Berger

UnternehmenPositionEnde
KEZAR LIFE SCIENCES, INC. Direktor/Vorstandsmitglied 11.05.2026
ESSA PHARMA INC. Direktor/Vorstandsmitglied 09.10.2025
ATRECA, INC. Direktor/Vorstandsmitglied 13.05.2024
RAIN ONCOLOGY INC. Direktor/Vorstandsmitglied 25.01.2024
░░░░░░ ░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Franklin Berger im Detail an

Ausbildung von Franklin Berger

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

65

Beziehungen ersten Grades

41

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen41

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Consumer Services

Health Technology

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Services

Health Technology

Finance

Health Technology

Commercial Services

NEMO Fund, Inc.

Health Technology

Health Technology

Consumer Services

Health Technology

Miscellaneous

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Finance

Health Technology

  1. Börse
  2. Insiders
  3. Franklin Berger